AAP
STRO icon

Arax Advisory Partners’s Sutro Biopharma STRO Stock Holding History

Arax Advisory Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75 Buy
41
+38
+1,267% +$687 ﹤0.01% 3635
2025
Q4 		$35 Sell
3
-381
-99% -$3.62K ﹤0.01% 3977
2025
Q3 		$3.34K Buy
+384
New +$3.27K ﹤0.01% 2983
2024
Q4 		– Sell
-66
Closed -$2.27K – 2734
2024
Q3 		$2.27K Hold
66
– – ﹤0.01% 2021
2024
Q2 		$1.93K Buy
+66
New +$2.61K ﹤0.01% 1979

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Arax Advisory Partners's STRO Position: Q1 2026 in Review

Arax Advisory Partners increased its Sutro Biopharma (STRO) stake by 1,267% in Q1 2026, buying an estimated $687 and bringing the position to 41 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #3635.

Arax Advisory Partners first reported a position in STRO in Q2 2024 and has held it in 5 quarters since. The position peaked at $3.34K in Q3 2025. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Arax Advisory Partners held 41 shares of Sutro Biopharma worth $75 as of Q1 2026.
  • Arax Advisory Partners bought 38 Sutro Biopharma shares in Q1 2026, an estimated $687.
  • Sutro Biopharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3635 holding.
  • Arax Advisory Partners first reported a position in Sutro Biopharma in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Sutro Biopharma position peaked at $3.34K in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.